Literature DB >> 11976941

Myosin light chain kinase modulates hypotonicity-induced Ca2+ entry and Cl- channel activity in human cervical cancer cells.

Meng-Ru Shen1, Paola Furla, Cheng-Yang Chou, J Clive Ellory.   

Abstract

Hypotonicity-induced Ca2+ entry is a critical signal for the normal regulatory volume decrease in human cervical cancer cells. The aim of this study was to explore the role of myosin light chain kinase (MLCK) in the regulation of hypotonicity-induced Ca2+ signalling and Cl- channel activity. Blockade of MLCK activity by MLCK(11-19) amide, a substrate-specific peptide inhibitor, markedly attenuated hypotonicity-induced Ca2+ entry. A similar result was obtained with ML-7, a synthetic naphthalenesulphonyl derivative that inhibits the binding of ATP to MLCK. More than 85% of the activity of the volume-regulated Cl- channel was suppressed when intracellular Ca2+ was buffered to near zero in the absence of extracellular Ca2+, suggesting that hypotonicity-induced Ca2+ signalling is important for the activation of the volume-regulated Cl- channel. Intracellular dialysis with MLCK(11-19) amide or ML-7 concentration-dependently reduced the amplitude and rate of activation of the volume-regulated Cl- channel. Swelling-activated taurine transport was also inhibited concentration dependently by ML-7 and MLCK(11-19) amide with IC(50) values of 6.4 and 2.0 microM, respectively. Hypotonicity induced MLC phosphorylation which was mediated totally by MLCK and depended on Ca2+ entry. However, phosphorylated MLC per se was not involved critically in the regulation of Ca2+ entry and activation of volume-sensitive organic osmolyte/anion channels (VSOAC). We propose that MLCK has a novel function in regulating the activation of VSOAC by mediating Ca2+ entry in response to hypotonicity. This function of MLCK on Ca2+ signalling does not correlate with MLC phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976941     DOI: 10.1007/s00424-002-0811-3

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  7 in total

1.  Differential effects of myosin light chain kinase inhibition on contractility, force development and myosin light chain 20 phosphorylation of rat cervical and thoracic duct lymphatics.

Authors:  Zhanna V Nepiyushchikh; Sanjukta Chakraborty; Wei Wang; Michael J Davis; David C Zawieja; Mariappan Muthuchamy
Journal:  J Physiol       Date:  2011-09-19       Impact factor: 5.182

2.  Murine vasa recta pericyte chloride conductance is controlled by calcium, depolarization, and kinase activity.

Authors:  Hai Lin; Thomas L Pallone; Chunhua Cao
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-08-04       Impact factor: 3.619

3.  Calcium is not required for triggering volume restoration in hypotonically challenged A549 epithelial cells.

Authors:  Olga Ponomarchuk; Francis Boudreault; Sergei N Orlov; Ryszard Grygorczyk
Journal:  Pflugers Arch       Date:  2016-10-31       Impact factor: 3.657

4.  Myosin phosphatase and myosin phosphorylation in differentiating C2C12 cells.

Authors:  Yue Wu; Ferenc Erdodi; Andrea Murányi; Kevin D Nullmeyer; Ronald M Lynch; David J Hartshorne
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

5.  Myosin light chain kinase and Src control membrane dynamics in volume recovery from cell swelling.

Authors:  Elisabeth T Barfod; Ann L Moore; Benjamin G Van de Graaf; Steven D Lidofsky
Journal:  Mol Biol Cell       Date:  2011-01-05       Impact factor: 4.138

6.  Improving the Understanding of Pathogenesis of Human Papillomavirus 16 via Mapping Protein-Protein Interaction Network.

Authors:  Yongcheng Dong; Qifan Kuang; Xu Dai; Rong Li; Yiming Wu; Weijia Leng; Yizhou Li; Menglong Li
Journal:  Biomed Res Int       Date:  2015-04-15       Impact factor: 3.411

Review 7.  Myosin Light Chain Kinase: A Potential Target for Treatment of Inflammatory Diseases.

Authors:  Yongjian Xiong; Chenou Wang; Liqiang Shi; Liang Wang; Zijuan Zhou; Dapeng Chen; Jingyu Wang; Huishu Guo
Journal:  Front Pharmacol       Date:  2017-05-23       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.